Skip to content

Cagrilintide vs Eloralintide

Updated 8 sources

Key differences

  1. 1Both are amylin agonists. Eloralintide is Lilly's selective amylin agonist; cagrilintide is Novo Nordisk's.
  2. 2Eloralintide's 48-week phase 2 reached 9% at 1 mg to 20% at 9 mg vs 0.4% on placebo. Cagrilintide alone reached 6.0 to 10.8% at 26 weeks in its phase 2.
  3. 3Community posters say eloralintide causes less fatigue, but its trial reported fatigue in 0 to 46% by arm (43% at 9 mg), so that impression is anecdotal.
  4. 4Eloralintide favors the amylin 1 receptor; cagrilintide also hits the calcitonin receptor.
  5. 5Half-life: about 310 to 366 hours for eloralintide vs 159 to 195 hours for cagrilintide.
  6. 6Phase 2 alone: eloralintide 9 mg -20% at 48 weeks; cagrilintide 4.5 mg -10.8% at 26 weeks. Different trial lengths, no head-to-head.
  7. 7In rats, eloralintide caused less taste avoidance (a nausea marker) than cagrilintide.

Side by side

Facts from each record, in the same words as their own pages.
Cagrilintide and Eloralintide side by side
CagrilintideEloralintide
Category
  • Weight loss
  • Weight loss
Evidence
  • Some human trials
  • Some human trials
FDA status
  • In clinical trialsRegulatory
  • In clinical trialsRegulatory
WADA
  • Not confirmed
  • Not confirmed
Half-life
  • About 7 to 8 days (159 to 195 hours). Levels peak 1 to 3 days after a dose. Measured at 0.16 to 4.5 mg alongside semaglutide.Clinical study
  • About 13 to 15 days (310 to 366 hours) after single doses of 0.04 to 12 mg in healthy adults; levels peak 72 to 132 hours after a shot.Clinical study
Routes
  • Subcutaneous injection
  • Subcutaneous injection
FormsNot reported
  • Vial (powder)
Reported doses
  • 0.1 to 4.5 mg (subcutaneous injection)
  • 0.5 to 12 mg (subcutaneous injection)
Most cited frequency
  • Once weekly, added from week 9
  • Once weekly at 1, 3, 6 or 9 mg depending on arm
Vial sizes
  • 5 mg, 10 mgCompetitor guide
  • 10 mg, 30 mgVendor guide
Mixed vial keeps
  • Keep the mixed vial at 2 to 8 °C, away from light, and use it within about 28 to 30 days.Community-reported
  • Fridge at 2 to 8 °C, protected from light.Vendor guide
Protocols on file
  • 13
  • 8

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

8 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory3

  1. Novo Nordisk submits NDA to FDA for CagriSemaPharmExec, via a news report · checked Oct 23, 2026
  2. openFDA Drugs@FDA query for eloralintideFDA (openFDA) · checked Oct 24, 2026
  3. ENLIGHTEN-1 (NCT07321886): eloralintide in obesity or overweight without type 2 diabetes, phase 3, recruitingClinicalTrials.gov · checked Oct 24, 2026